AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Enteral Nutrition Delivery in Prone Position Ventilated Patients With Moderate to Severe ARDS

RecruitingNAAges 18 Years - 85 YearsAllSoutheast University, China
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This pilot study is aimed to compare and assess the impact, safety, and practical utility of gastric versus postpyloric feeding in moderate to severe ARDS patients with prone position ventilation. Patients included will be randomly assigned to receive enteral nutrition either through a nasogastric tube or a nasojejunal tube. The primary endpoint is the achievement of enteral nutrition goals. Secondary endpoints include the incidence of hospital-acquired infections, the number of ventilator-free days within 28 days, ICU length of stay, ICU mortality, 28-day mortality, 60-day mortality rates, the incidence of enteral nutrition intolerance, and the rate of enteral nutrition intake.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * ARDS patients who meet the Berlin criteria for ARDS and have a P/F ratio โ‰ค 200mmHg. * Patients receiving invasive mechanical ventilation and clinically judged to require prone ventilation, with an anticipated daily prone positioning time of โ‰ฅ12 hours and a duration of prone ventilation therapy of โ‰ฅ3 days. * Patients planned to receive enteral nutrition. * Age โ‰ฅ18 and โ‰ค85 years. * Consent to sign an informed consent form. Exclusion Criteria: * Contraindications to enteral nutrition, such as severe intestinal ischemia, active upper gastrointestinal bleeding, high-output intestinal fistula without a distal feeding route, abdominal compartment syndrome, severe diarrhea, intestinal obstruction, etc. * Presence of shock with hemodynamic instability (norepinephrine or equivalent vasopressor dosage โ‰ฅ0.5ug/kg.min) or tissue hypoperfusion (lactate \>3mmol/L). * Life-threatening hypoxemia, hypercapnia, and acidosis. * Inability to tolerate prone ventilation (e.g., pregnant women, limb contractures, recent fractures, recent thoracic or abdominal surgery, pacemaker insertion within 48 hours, spinal instability, pelvic fractures, facial fractures, anticipated difficult airway). * Conditions preventing nasogastric or nasojejunal tube placement (e.g., esophageal rupture, severe esophageal varices). * Anticipated inability to start enteral nutrition within 48 hours. * Use of prokinetic agents within 48 hours prior to starting enteral nutrition. * Enteral nutrition via gastrostomy or jejunostomy. * Expected ICU stay or survival time less than 3 days. * Patients refusing further resuscitative treatment. * Pregnant or breastfeeding women. * Patients already enrolled in other interventional clinical studies or deemed unsuitable for the study by the clinician.
๐Ÿ’Š

What it tests

  • enteral nutrition through nasojejunal tube
  • enteral nutrition through nasogastric tube
๐Ÿ“

Where

1 site
Zhongda hospital, Southeast university
Nanjing, China
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy